Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease
Mesalazine is widely used in the treatment of inflammatory bowel disease. Little is known about the doseresponse relationship and about possible dose related side effects. In ulcerative colitis higher dosages of mesalazine (3 g) are more effective in maintaining a remission than lower dosages (1.5 g...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
1998-01-01
|
| Series: | Mediators of Inflammation |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09629359891027 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832565073692852224 |
|---|---|
| author | C. J. J. Mulder S. J. Van Den Hazel |
| author_facet | C. J. J. Mulder S. J. Van Den Hazel |
| author_sort | C. J. J. Mulder |
| collection | DOAJ |
| description | Mesalazine is widely used in the treatment of inflammatory bowel disease. Little is known about the doseresponse relationship and about possible dose related side effects. In ulcerative colitis higher dosages of mesalazine (3 g) are more effective in maintaining a remission than lower dosages (1.5 g). In mild to moderately active ulcerative colitis, studies also indicate that higher dosages might be more effective in inducing remission. Dose-comparing studies in Crohn's disease are even more sparse, but the available results indicate higher efficacy at higher dose levels. |
| format | Article |
| id | doaj-art-0af5646798784b44b79f119c1164cc99 |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 1998-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-0af5646798784b44b79f119c1164cc992025-02-03T01:09:25ZengWileyMediators of Inflammation0962-93511466-18611998-01-017313513610.1080/09629359891027Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel diseaseC. J. J. Mulder0S. J. Van Den Hazel1Department of Gastroenterology, Rijnstate Hospital, P O Box 9555, Arnhem, The NetherlandsDepartment of Gastroenterology, Rijnstate Hospital, P O Box 9555, Arnhem, The NetherlandsMesalazine is widely used in the treatment of inflammatory bowel disease. Little is known about the doseresponse relationship and about possible dose related side effects. In ulcerative colitis higher dosages of mesalazine (3 g) are more effective in maintaining a remission than lower dosages (1.5 g). In mild to moderately active ulcerative colitis, studies also indicate that higher dosages might be more effective in inducing remission. Dose-comparing studies in Crohn's disease are even more sparse, but the available results indicate higher efficacy at higher dose levels.http://dx.doi.org/10.1080/09629359891027mesalazineinflammatory bowel diseaseCrohn's disease ulcerative colitissafetyside effectsdrug therapy dose-response. |
| spellingShingle | C. J. J. Mulder S. J. Van Den Hazel Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease Mediators of Inflammation mesalazine inflammatory bowel disease Crohn's disease ulcerative colitis safety side effects drug therapy dose-response. |
| title | Drug therapy: dose-response relationship of oral mesalazine in
inflammatory bowel disease |
| title_full | Drug therapy: dose-response relationship of oral mesalazine in
inflammatory bowel disease |
| title_fullStr | Drug therapy: dose-response relationship of oral mesalazine in
inflammatory bowel disease |
| title_full_unstemmed | Drug therapy: dose-response relationship of oral mesalazine in
inflammatory bowel disease |
| title_short | Drug therapy: dose-response relationship of oral mesalazine in
inflammatory bowel disease |
| title_sort | drug therapy dose response relationship of oral mesalazine in inflammatory bowel disease |
| topic | mesalazine inflammatory bowel disease Crohn's disease ulcerative colitis safety side effects drug therapy dose-response. |
| url | http://dx.doi.org/10.1080/09629359891027 |
| work_keys_str_mv | AT cjjmulder drugtherapydoseresponserelationshipoforalmesalazineininflammatoryboweldisease AT sjvandenhazel drugtherapydoseresponserelationshipoforalmesalazineininflammatoryboweldisease |